Original Investigation
HSCT vs Cyclophosphamide in Systemic Sclerosis
Jacob M. van Laar, MD, PhD; Dominique Farge, MD, PhD; Jacob K. Sont, PhD; Kamran Naraghi, MD; Zora Marjanovic, MD; Jérôme Larghero, PharMD, PhD; Annemie J. Schuerwegh, MD, PhD; Erik W. A. Marijt, MD, PhD; Madelon C. Vonk, MD, PhD; Anton V. Schattenberg, MD, PhD; Marco Matucci-Cerinic, MD, PhD; Alexandre E. Voskuyl, MD, PhD; Arjan A. van de Loosdrecht, MD, PhD; Thomas Daikeler, MD; Ina Kötter, MD, PhD; Marc Schmalzing, MD; Thierry Martin, MD, PhD; Bruno Lioure, MD; Stefan M. Weiner, MD; Alexander Kreuter, MD; Christophe Deligny, MD; Jean-Marc Durand, MD, PhD; Paul Emery, MD; Klaus P. Machold, MD; Francoise Sarrot-Reynauld, MD, PhD; Klaus Warnatz, MD; Daniel F. P. Adoue, MD; Joël Constans, MD; Hans-Peter Tony, MD; Nicoletta Del Papa, MD, PhD; Athanasios Fassas, MD; Andrea Himsel, MD; David Launay, MD, PhD; Andrea Lo Monaco, MD, PhD; Pierre Philippe, MD; Isabelle Quéré, MD, PhD; Éric Rich, MD; Rene Westhovens, MD, PhD; Bridget Griffiths, MD; Riccardo Saccardi, MD; Frank H. van den Hoogen, MD, PhD; Willem E. Fibbe, MD, PhD; Gérard Socié, MD, PhD; Alois Gratwohl, MD; Alan Tyndall, MD; for the EBMT/EULAR Scleroderma Study Group
JAMA